$2.64
1.52%
Downside
Day's Volatility :8.77%
Upside
7.37%
34.09%
Downside
52 Weeks Volatility :88.0%
Upside
81.79%
Period | Fractyl Health, Inc. | Index (Russel 2000) |
---|---|---|
3 Months | -51.29% | 0.0% |
6 Months | -57.76% | 0.0% |
1 Year | -79.46% | 0.0% |
3 Years | -79.46% | -20.9% |
Market Capitalization | 133.7M |
Book Value | $1.48 |
Earnings Per Share (EPS) | -1.37 |
Wall Street Target Price | 15.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -53453.49% |
Return On Assets TTM | -48.23% |
Return On Equity TTM | -169.24% |
Revenue TTM | 119.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -40.300000000000004% |
Gross Profit TTM | 0.0 |
EBITDA | -71.0M |
Diluted Eps TTM | -1.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 487.12%
Sell
Neutral
Buy
Fractyl Health, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Fractyl Health, Inc. | -2.94% | -57.76% | -79.46% | -79.46% | -79.46% |
Regeneron Pharmaceuticals, Inc. | -3.66% | 20.12% | 39.85% | 76.89% | 300.21% |
Novo Nordisk A/s | 1.22% | 3.02% | 46.72% | 169.99% | 437.18% |
Alnylam Pharmaceuticals, Inc. | -1.5% | 83.41% | 50.4% | 42.05% | 207.87% |
Vertex Pharmaceuticals Incorporated | 0.28% | 18.97% | 39.04% | 159.92% | 178.09% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Fractyl Health, Inc. | NA | NA | NA | 0.0 | -1.69 | -0.48 | NA | 1.48 |
Regeneron Pharmaceuticals, Inc. | 30.58 | 30.58 | 1.57 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 46.28 | 46.28 | 2.09 | 3.43 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Fractyl Health, Inc. | Buy | $133.7M | -79.46% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $127.1B | 300.21% | 30.58 | 32.04% |
Novo Nordisk A/s | Buy | $606.9B | 437.18% | 46.28 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.1B | 207.87% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $126.3B | 178.09% | 32.84 | -4.74% |
Organization | Fractyl Health, Inc. |
Employees | 112 |
CEO | Dr. Harith Rajagopalan M.D., Ph.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$2.64
-5.38%
Keyarch Acquisition Corp
$2.64
-5.38%
Connexa Sports Technologies Inc
$2.64
-5.38%
Us Value Etf
$2.64
-5.38%
First Wave Biopharma Inc
$2.64
-5.38%
Global X Msci Next Emerging
$2.64
-5.38%
Fat Projects Acquisition Corp
$2.64
-5.38%
Capital Link Global Fintech
$2.64
-5.38%
Applied Uv Inc
$2.64
-5.38%